Johnson & Johnson Statement on Outcome of Global Drug Facility Tender for Generic Forms of SIRTURO® 100mg (bedaquiline)

The introduction of generic forms of SIRTURO® 100mg (bedaquiline), our medicine for multidrug-resistant tuberculosis (MDR-TB), in low-and middle-income countries is an example of the lifecycle for medicines. It is made possible by Johnson & Johnson’s investments in innovation on behalf of the patients we serve, and our continuing, collaborative and patient-focused efforts with Stop TB Partnership’s Global Drug Facility and many other partners. Generic forms of SIRTURO®100mg will not solve MDR-TB. Underdiagnosis remains the most significant barrier to treatment, with nearly two-thirds of the 450,000 people who develop MDR-TB each year not diagnosed and enrolled on treatment. We have dedicated significant resources to overcome this challenge and we must all get behind it and work together if we are to save lives and achieve the global goal of ending TB. Discover J&J News Our Credo & our purpose Leadership Social impact Suppliers Our history Policies & reports Environmental sustainability Medicines & therapies Products Oncology Immunology Neuroscience Cardiopulmonary Medical devices & technology Products Cardiovascular Orthopaedics Surgery Vision About us Our company Medicines & therapies Medical devices & technology Careers Investors Media Key links Terms of use Privacy Cookie policy Customize cookie settings Digital Accessibility Statement Get in touch Contact Socials linkedin instagram facebook twitter This website is intended for U.S. audiences only. Do not sell or share my personal information Limit the use of my sensitive personal information © Johnson & Johnson and its affiliates 2026

The release as fetched from its publisher. jnj.com ↗